FDA
-
-
-
-
-
-
-
William Blair on Larimar Therapeutics (LRMR): not without risk but favorable risk/reward
-
-
-
-
-
-
-
Leerink Partners Assumes Larimar Therapeutics (LRMR) at Outperform
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Larimar Therapeutics (LRMR)
-
-
-
-
-
-
-
Leerink Partners Reiterates Outperform Rating on Larimar Therapeutics (LRMR)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Larimar Therapeutics (LRMR)
-
-
-
-
-
-
-
Leerink Partners Reiterates Outperform Rating on Larimar Therapeutics (LRMR)
-
-
-
-
-
-
-
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024
-
324,250 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

